Mineralys Therapeutics, Inc. 8-K

What Happened
Mineralys Therapeutics, Inc. filed an 8-K on June 3, 2026 announcing an underwritten public offering of 5,660,378 shares of its common stock at a public offering price of $26.50 per share. The offering is led by BofA Securities, Goldman Sachs & Co. LLC and Evercore Group L.L.C., and is expected to close on June 4, 2026, subject to customary closing conditions.

Key Details

• Total shares offered: 5,660,378 common shares.
• Public offering price: $26.50 per share (gross proceeds ≈ $150.0 million).
• Purchase price to Mineralys from underwriters: $25.3075 per share.
• Expected net proceeds to the company: approximately $142.5 million after underwriting discounts, commissions and estimated offering expenses.
• Offering made under the company’s effective Form S-3 registration statement; underwriting agreement contains customary representations, indemnities and closing conditions.

Why It Matters

• The offering will bring roughly $142.5 million in net proceeds to Mineralys if it closes, providing additional capital for the company.
• Issuing 5.66 million new shares will dilute existing shareholders’ ownership proportionately.
• Completion remains subject to customary closing conditions and market factors; the filing includes the company’s standard forward-looking caution about risks and uncertainties.